Groundbreaking Malaria Vaccine Rollout Sweeps Africa, Saving Lives
カートのアイテムが多すぎます
ご購入は五十タイトルがカートに入っている場合のみです。
カートに追加できませんでした。
しばらく経ってから再度お試しください。
ウィッシュリストに追加できませんでした。
しばらく経ってから再度お試しください。
ほしい物リストの削除に失敗しました。
しばらく経ってから再度お試しください。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
Groundbreaking Malaria Vaccine Rollout Sweeps Africa, Saving Lives
-
ナレーター：
-
著者：
このコンテンツについて
As of early April 2025, 19 African countries, including Benin, Burkina Faso, Burundi, Cameroon, and others, have integrated the RTS,S and R21 malaria vaccines into their childhood immunization programs and national malaria control strategies. This widespread adoption follows the World Health Organization's (WHO) prequalification of the RTS,S vaccine in July 2022 and the R21 vaccine in December 2023, ensuring the vaccines' safety and quality[5].
One of the most notable recent initiatives is Uganda's launch of the largest malaria vaccine introduction to date. The R21/Matrix-M malaria vaccine, administered in four doses at 6, 7, 8, and 18 months, is initially targeting 1.1 million children under the age of two. This effort underscores the commitment to protecting young children, who are among the most vulnerable to the disease[1].
Mali has also made significant strides, becoming the 20th African country to introduce the malaria vaccine on World Malaria Day in April 2025. The introduction of the vaccine in Mali marks a critical milestone, following 35 years of research and development. UNICEF is supporting community engagement efforts, utilizing digital tools and young volunteers to promote vaccination and counter misinformation[3].
The impact of these vaccines has already been evident. Between 2019 and 2023, over 2 million children in Ghana, Kenya, and Malawi received the RTS,S/AS01 malaria vaccine through the Malaria Vaccine Implementation Programme (MVIP), resulting in a 13% reduction in mortality among age-eligible children. This success has bolstered the WHO's recommendation and prequalification of the current malaria vaccines[3].
Despite these advancements, there are also challenges. The FDA recently paused BioNTech's phase 1/2a trial of its experimental malaria vaccine, BNT165e, due to unspecified concerns. This pause highlights the ongoing scrutiny and rigorous testing that new vaccine candidates must undergo to ensure safety and efficacy[4].
Overall, the demand for malaria vaccines remains unprecedented, with at least 30 African countries planning to introduce these vaccines into their immunization programs. The availability of two safe and effective vaccines, RTS,S and R21, is expected to meet this high demand, offering a powerful new tool in the fight against this life-threatening disease[5].